Everything below concerns certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-23. Numbers and descriptions here follow the published literature rather than marketing material.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
== Births == 13 December - Robert Griffiths, inventor (died 1883) 19 December - John David Edwards, hymn-writer (died 1885) date unknown Evan Davies, missionary (died 1864) Hugh Hughes (Tegai), writer (died 1864) John William Thomas, mathematician (died 1840)
The bonnet is usually a copper shell with soldered brass fittings. It covers the diver's head and provides sufficient space to turn the head to look out of the glazed faceplate and other viewports (windows). The front port can usually be opened for ventilation and communication when the diver is on deck, by being screwed out or swung to the side on a hinge. The other lights (another name for the viewports) are generally fixed. Viewports were glass on the early helmets, with some of the later helmets using acrylic, and are usually protected by brass or bronze grilles. The helmet has fittings to connect the air line and the diver's telephone. All except the earliest helmets include a non-return valve where the airline is connected, which prevents potentially fatal helmet squeeze if the pressure in the hose is lost. The difference in pressure between the surface and the diver can be so great that if the air line is cut at or near the surface and there is no non-return valve, the diver would be partly squeezed into the helmet by the external pressure, and injured or possibly killed. Helmets also have a spring-loaded exhaust valve which allows excess air to leave the helmet. The spring force is adjustable by the diver to prevent the suit from deflating completely or over-inflating and the diver being floated uncontrollably to the surface. Some helmets have an extra manual valve known as a spit-cock, which can be used to vent excess air when the diver is in a position where the main exhaust can not function correctly.
== Career == Larsen worked for more than 35 years at DuPont. In her research in mass spectrometry, she worked with a number of ionization sources, from electrospray ionization, matrix-assisted laser desorption/ionization, solid probe introduction with corona discharge ionization, to laserspray ionization. Her fluorinated polymer extraction method, the Larsen method, is required by the Environmental Protection Agency for consumer safety. She is a consultant at Larsen Scientific Consulting. She serves on the editorial advisory board of Spectroscopy. She was an editor for the Journal of the American Society for Mass Spectrometry. She served on a number of board positions for the American Society for Mass Spectrometry: treasurer (1992-1994), vice president for programs (2004-2006), president (2006-2008), and past president (2008-2010). She was elected as an American Chemical Society Fellow in 2017.
Valve integrated the Havok physics engine, which simulates real-world physics, to reinforce the player's sense of presence and create new gameplay. To experiment, they created a minigame, Zombie Basketball, in which players used a physics-manipulating gun to throw zombies through hoops. In mid-2000, to test the physics and non-player characters, Valve built a battle between rioting citizens and police. In late 2001, Valve began creating a showreel, hoping to demonstrate it at E3 the next year. For several months, Newell let the team work without his input so he could provide unbiased feedback, and focused on developing Steam, Valve's upcoming digital distribution service. The team presented the showreel to Newell, showcasing physics, environments such as the Borealis, and a dialogue-heavy scene with the scientist character Dr. Kleiner. Newell felt the showreel did not adequately show how the physics would affect gameplay and that the Kleiner scene was overlong. Reflecting on the feedback, Laidlaw concluded that the character drama had to support interactivity and gameplay. In September 2002, the team completed a second showreel, featuring a buggy race along the City 17 coast, an encounter with headcrabs on a pier, an alien strider attacking the city, and a greatly shortened Kleiner sequence. In October, Newell told the team they would announce Half-Life 2 at E3 2003 and release it by the end of the year. As with the original Half-Life, the team split into "cabals" working on different levels.
Valproate (valproic acid, VPA, sodium valproate, or valproate semisodium) is a medication primarily used to treat epilepsy and as a mood stabilizer in the treatment of bipolar disorder. It is useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures. It can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations. Common side effects of valproate include nausea, vomiting, somnolence, and dry mouth. Serious side effects can include liver failure, and regular monitoring of liver function tests is therefore recommended. Other serious risks include pancreatitis and an increased suicide risk. Valproate is known to cause serious abnormalities or birth defects in the fetus if taken during pregnancy, and is contra-indicated for women of childbearing age unless the drug is essential to their medical condition and the person is also prescribed a contraceptive. Reproductive warnings have also been issued for men using the drug. Valproate is restricted in the United Kingdom for both women and men under age 55 due to teratogenicity in pregnant women and fertility problems in men. It is also restricted in the European Union. The United States Food and Drug Administration has indicated a black box warning given the frequency and severity of the side effects and teratogenicity. Additionally, there is also a black box warning due to risk of hepatotoxicity and pancreatitis. Valproate has been in use in Japan for the prophylaxis of migraine since 2011.
Sources: en.wikipedia.org
The first document, which was leaked at the end of January, was a "draft version of the Progressive Conservative government's upcoming health-care transformation legislation." CTV News said "local health integration networks, Cancer Care Ontario, eHealth Ontario, the Trillium Gift of Life Network and other government health agencies" would be "rolled into" the super agency. Minister Elliot said that the December 13 assistant deputy ministers workshop document, which made references to outsourcing laboratories, "inspections, licensing, devices" and Ornge, were options and that these services would not be privatized. The NDP said that the super agency was described in the leaked documents as having the "competency and capacity to effectively partner with public and private sector entities." The documents show that MyCare groups is being created as a "new model" of "integrated care delivery" with the goal of providing "patients with seamless, co-ordinated care and a single team of providers for all their care needs." Ontario Health Minister Christine Elliot tabled the controversial Bill 74: The People's Health Care Act. Its first reading was on February 26, 2019, and it received Royal Assent on April 18, 2019.
Vacutainer tubes may contain additional substances that preserve blood for processing in a medical laboratory. Using the wrong tube may make the blood sample unusable for the intended purpose. These additives are typically thin film coatings applied using an ultrasonic nozzle. The additives may include anticoagulants (EDTA, sodium citrate, heparin) or a gel with density between those of blood cells and blood plasma. Additionally, some tubes contain additives that preserve certain components of or substances within the blood, such as glucose. When a tube is centrifuged, the materials within are separated by density, with the blood cells sinking to the bottom and the plasma or serum accumulating at the top. Tubes containing gel can be easily handled and transported after centrifugation without the blood cells and serum mixing.
In organic chemistry, a carbodiimide (systematic IUPAC name: methanediimine) is a functional group with the formula RN=C=NR. On Earth they are exclusively synthetic, but in interstellar space the parent compound HN=C=NH has been detected by its maser emissions. A well known carbodiimide is dicyclohexylcarbodiimide, which is used in peptide synthesis. Dialkylcarbodiimides are stable. Some diaryl derivatives tend to convert to dimers and polymers upon standing at room temperature, though this mostly occurs with low melting point carbodiimides that are liquids at room temperature. Solid diaryl carbodiimides are more stable, but can slowly undergo hydrolysis in the presence of water over time.
== Prevention == Up to 90% of cardiovascular disease may be preventable if established risk factors are avoided. Medical management of atherosclerosis first involves modification to risk factors–for example, via smoking cessation and diet restrictions. Prevention is generally achieved by eating a healthy diet, exercising, maintaining a normal weight, and not smoking.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.